Earnings digests and industry comparisons for Japan's biggest listed companies.
237 reports(page 5 of 20)
Resorttrust disclosed on Oct.7 that approx 62,000 customers' data was exposed via unauthorized web access. While smaller than industry averages, the mix of guest profiles poses potential management risks.
HOYA announced the sale of its US vitreous surgery subsidiary, MID Labs, to Bausch + Lomb. The deal is part of a portfolio review to concentrate resources on core businesses, with minimal impact on current consolidated earnings.
Round One disclosed that September same-store sales rose 38.6%, powered by a 53.2% jump in the amusement segment. Accumulated sales for the first half of the fiscal year also showed robust growth of 21.8%.
Sugi HD revised its full-year profit forecast downward due to poor summer weather impacting demand, despite revenue gains from its Sekiyaku integration. The drugstore operator now expects net income of 27.4 billion yen for the fiscal year ending February 2027.
Rorze announced a significant upward revision to its full-year consolidated earnings forecast, driven by robust semiconductor demand. The company projects record net income and a dividend increase of 64.7 percent to 28 yen per share.
Rakus disclosed that Singapore-based Ichigo Trust PTE Limited expanded its voting rights ratio on Oct 8, 2026. The investor now holds 10.38 percent of shares, rising to the second-largest position.
Nihon M&A Center announced that its mid-term dividends in December 2024 and 2025 exceeded the distributable amount under Company Law. The company has launched an independent third-party committee to investigate the breach.
Fast Retailing (9983) raised its full-year dividend forecast to 850 yen per share for the August 2026 term, a significant increase from the previous estimate of 640 yen. This marks a roughly 70% year-on-year growth and sets a new all-time high. The move reflects strong global profitability supporting both high-growth investment and substantial shareholder returns.
Medical equipment giant Terumo will recognize a massive loss of approximately $610 million due to the termination of a key supply contract. Consequently, the company has revised its full-year operating profit forecast downward by roughly 38 percent.
Ono has secured exclusive rights to develop IgG-degrading drugs in key Asian markets through a partnership with US-based Biohaven. The agreement involves an upfront payment of $80 million and aims to expand Ono's pipeline beyond oncology into autoimmune diseases.
Daiwabo completed its treasury stock acquisition program, achieving a de facto full execution of the 6 billion yen cap. The company bought 1.69 million shares worth 5.9997 billion yen, signaling strong capital efficiency goals to investors.
Mitsubishi Motors has reached a settlement in a lawsuit involving its US subsidiary, Mitsubishi Motors North America. The company stated that the legal dispute is now concluded and will not change its current financial forecasts.
